Sign In
Buy CGIX
$1.08
+0 (+0%)
At Close: May 27, 2022
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO
12:00am, Tuesday, 27'th Aug 201925 Healthcare Stocks Moving In Wednesday's Pre-Market Session
12:00am, Wednesday, 21'st Aug 2019Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
12:00pm, Tuesday, 20'th Aug 2019
RUTHERFORD, N.J., Aug. 20, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.
